Evidence map›Paper›PMID 35901338›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Clinical Features of Fecal Immunochemical Test-Negative Colorectal Lesions based on Colorectal Cancer Screening among Asymptomatic Participants in Their 50s.

Shinya Suto, Masashi Matsuzaka, Manabu Sawaya, Hirotake Sakuraba, Tatsuya Mikami, Takahisa Matsuda, Takahiro Fujii, Yutaka Saito, Kinichi Hotta, Hiroaki Ikematsu and 4 more

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Shinya SutoDepartment of Gastroenterology and Haematology, Hirosaki University Graduate School of Medicine 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.ORCID 0000-0002-9906-4906
Masashi MatsuzakaDepartment of Medical Informatics, Hirosaki University Hospital, 53 Honcho, Hirosaki, Aomori 036- 8563, Japan.
Manabu SawayaDepartment of Gastroenterology and Haematology, Hirosaki University Graduate School of Medicine 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.
Hirotake SakurabaDepartment of Gastroenterology and Haematology, Hirosaki University Graduate School of Medicine 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.
Tatsuya MikamiInnovation Center for Health Promotion, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036- 8562, Japan.
Takahisa MatsudaDivision of Gastroenterology and Hepatology, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Japan.
Takahiro FujiiTF Clinic, Ginza M&S building 7F, 4-13-11 Ginza, Chuo-ku, Tokyo 104-0061, Japan.
Yutaka SaitoEndoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Kinichi HottaDivision of Endoscopy, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
Hiroaki IkematsuDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Norihiro HanabataDepartment of Gastroenterology, Aomori Prefectural Central Hospital, 2-1-1, Higashi-Tsukurimichi, Aomori 030-8553, Japan.
Hiroshi SaitoAomori Prefectural Central Hospital, 2-1-1, Higashi-Tsukurimichi, Aomori 030-8553, Japan.
Shigeaki YoshidaAomori Prefectural Central Hospital, 2-1-1, Higashi-Tsukurimichi, Aomori 030-8553, Japan.
Shinsaku FukudaDepartment of Gastroenterology and Haematology, Hirosaki University Graduate School of Medicine 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.
National Cancer Center Hospital East · JPShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo improve the efficacy of colorectal cancer (CRC) screening, decreasing the occurrence of interval cancers is essential. Most interval CRCs develop from fecal immunochemical test (FIT)-negative CRC. This study examined the clinical characteristics of FIT-negative advanced neoplasms (AN) and sessile serrated lesions (SSL), which are main candidate precursors of FIT-negative CRC, and the eligibility criteria for total colonoscopy (TCS) screening following negative FIT.

methodsAsymptomatic participants in their 50s were divided into two groups. The FIT-negative group underwent TCS following negative FIT, and the TCS-only group underwent TCS without FIT. One endoscopist reviewed the endoscopic images. Plausible risk factors for colorectal polyps were extracted. The clinical features of AN and SSL were compared between the groups.

resultOf 2,437 participants, 56.2% were included in the FIT-negative group. No between-group differences were recorded for the prevalence of different colorectal polyp types. By multivariate analysis, a significantly lower adjusted odds ratio (AOR) of AN was shown in women, and significantly higher AORs of AN were found for aging, smoking, and a family history of CRC. The AOR of SSL was higher for smokers. The proportion of AN in the right colon was higher in the FIT-negative group. No between-group differences were recorded for SSL.

conclusionFIT screening was less likely to detect CRC and certain precancerous lesions in the right colon. Combining annual FIT with TCS for the high-risk population based on a scoring system, may detect FIT-negative CRC and colorectal polyps, thus, reducing interval cancer.

Indexed as

AdenomaColonic PolypsColorectal NeoplasmsColonoscopyEarly Detection of CancerFecesFemaleHumansMass ScreeningOccult Bloodcolonic polypsEarly Detection of CancerTotal Colonoscopy

Identifiers

PMID35901338
PMCPMC9727366
OpenAlexW4288388793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.